Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Plasmacytoma 1Multiple Myeloma 1Carcinoma, Basal Cell 1

Interventions

Photochemotherapy 41-phenyl-3,3-dimethyltriazene 4sonidegib 2pembrolizumab 2HhAntag691 2Biopsy 2tozuleristide 1tocilizumab 1talimogene laherparepvec 1silmitasertib 1prednylidene 1poly ICLC 1flt3 ligand protein 1deltacortene 1cemiplimab 1Tacrolimus 1TAK-441 1Sirolimus 1SUB1 protein, human 1Radiotherapy 1Radiation 1Prednisone 1Nivolumab 1NVP-LEQ506 1Microarray Analysis 1Mass Spectrometry 1Laser Therapy 1Ipilimumab 1Imiquimod 1Glatiramer Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Basal Cell × silmitasertib × Clear all
NCT03897036 2025-05-20

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Senhwa Biosciences, Inc.

Phase 1 Completed
25 enrolled 9 charts
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡